You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 137 No. 9, September 2002 TABLE OF CONTENTS
  Archives
  •  Online Features
  Paper
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (27)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Women's Health
 •Menopause
 •Diagnosis
 •Breast Cancer
 •Alert me on articles by topic

The Impact of Hormone Replacement Therapy on the Detection and Stage of Breast Cancer

Julie Cheek, MD; Judith Lacy, MD; SuEllen Toth-Fejel, PhD; Katherine Morris, MD; Kristine Calhoun, MD; Rodney F. Pommier, MD

Arch Surg. 2002;137:1015-1021.

Hypothesis  Patients who receive hormone replacement therapy (HRT) and subsequently develop breast cancer are more likely to be diagnosed by palpation than mammography and have a higher stage of cancer at initial diagnosis.

Design  Retrospective case series.

Setting  University hospital.

Patients  Two hundred ninety-two patients with breast cancer who were postmenopausal.

Interventions  Clinical examination, mammography, and definitive therapy.

Main Outcome Measures  Hormone replacement therapy use, mode of cancer detection, tumor size, nodal status, stage, and survival.

Results  Patients receiving HRT prior to diagnosis had significantly more incidences of mammographically detected tumors, ductal carcinoma in situ, T1 lesions, negative nodes, and better survival rates than nonusers.

Conclusions  A history of HRT use had only beneficial and no discernible adverse effects on breast cancer detection and outcomes. These effects of HRT seem to be due to the development of less aggressive tumors rather than earlier detection.


From the Section of Surgical Oncology, Department of General Surgery, Oregon Health and Sciences University, Portland (Drs Lacy, Toth-Fejel, Morris, Calhoun, and Pommier); and the Department of General Surgery, Akron General Medical Center, Akron, Ohio (Dr Cheek).



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prediagnostic Use of Hormone Therapy and Mortality After Breast Cancer
Newcomb et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:864-871.
ABSTRACT | FULL TEXT  

Breast Cancer Risk in Postmenopausal Women Using Estrogen-Only Therapy
Lyytinen et al.
Obstet Gynecol 2006;108:1354-1360.
ABSTRACT | FULL TEXT  

A Predictive Model for the Development of Hormone-Responsive Breast Cancer
Gorla et al.
Ann. Surg. Oncol. 2005;12:48-56.
ABSTRACT | FULL TEXT  

Performance and Reporting of Clinical Breast Examination: A Review of the Literature
McDonald et al.
CA Cancer J Clin 2004;54:345-361.
ABSTRACT | FULL TEXT  

The Characteristics of Malignant Breast Tumors in Hormone Replacement Therapy Users Versus Nonusers
Pappo et al.
Ann. Surg. Oncol. 2004;11:52-58.
ABSTRACT | FULL TEXT  

Prognostic Characteristics of Breast Cancer Among Postmenopausal Hormone Users in a Screened Population
Kerlikowske et al.
JCO 2003;21:4314-4321.
ABSTRACT | FULL TEXT  

Menopausal Hormone Therapy and Breast Cancer Detection and Outcomes
JWatch Women's Health 2002;2002:2-2.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.